An antifibrinolytic agent, ε-aminocaproic acid (EACA), has been used for treatment; however, data regarding its efficacy and safety in this setting are limited. This retrospective, single-center ...

Adjunctive therapies such as the antifibrinolytic agent aminocaproic acid (ACA) have also been proposed, 15 and over 60% of ICU patients with DAH in our institution receive intravenous ACA despite ...

Aminocaproic acid 250mg/mL; soln for IV infusion after dilution; contains benzyl alcohol. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a full text component.

We sought to determine whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clinically important consequences.

Aprotinin has recently been associated with adverse outcomes in patients undergoing cardiac surgery. We reviewed our experience with this agent in patients undergoing cardiac surgery at Duke ...

(“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current annual U.S ...

Aminocaproic acid 500mg, 1000mg; scored tabs. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this ...

Aminocaproic Acid is an antidote, prescribed for excessive bleeding caused by fibrinolytic drugs. The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with ...

Details concerning the Aminocaproic acid medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids ...